Statute Details
- Title: Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021
- Act Code: HPA2007-S104-2021
- Legislation Type: Subsidiary legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D)
- Enacting Authority: Health Sciences Authority (HSA), with Minister for Health’s approval
- Status: Current version (as at 27 Mar 2026)
- Commencement: Not stated in the provided extract (see official commencement in the instrument)
- Key Structure: Part 1 (Preliminary) to Part 10 (General provisions), plus Schedule (repealed)
- Key Provisions (from extract): Definitions (s 2); Clinical research CTGT products excluded (s 3); Licensing and exceptions for manufacture/import/supply; Registration requirements (ss 29–30); Duties and obligations (ss 31–51); Certification (ss 52–55); General provisions (ss 56–60)
- Notable Amendments (timeline in extract): SL 104/2021 (1 Mar 2021); S 1076/2021 (3 Jan 2022); S 451/2022 (1 Jul 2022); S 437/2023 (26 Jun 2023 and 31 Dec 2021 version reference); S 801/2023 (18 Dec 2023)
- Related Legislation (as provided): Health Products Act; Healthcare Services Act 2020; Medical Registration Act 1997; Dental Registration Act 1999
What Is This Legislation About?
The Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (“CTGT Regulations”) form Singapore’s regulatory framework for cell, tissue and gene therapy products—often referred to as “CTGT products”. These are advanced therapies that can involve living cells, tissues, or genetic material used to treat, prevent, or diagnose disease. Because of their complexity and potential risks, the Regulations impose licensing, registration, quality, traceability, and reporting obligations across the lifecycle of CTGT products.
In plain language, the Regulations aim to ensure that CTGT products made, imported, supplied, presented to patients, and administered in Singapore meet defined standards of quality, safety, and information transparency. They also create a structured system for oversight by the Health Sciences Authority (HSA), including requirements for record-keeping, traceability, adverse event reporting, and recall notifications.
The Regulations are not limited to commercial manufacturers. They also address research and non-clinical contexts through specific exceptions, and they regulate wholesale and retail supply, including how products are described and what information must accompany them. The framework distinguishes between “minimally manipulated” products and other CTGT products, and between “Class 1” and “Class 2” CTGT products, which affects whether licensing/registration is required and what additional consent or information duties apply.
What Are the Key Provisions?
1) Preliminary scope and exclusions. Part 1 sets out definitions and key scope rules. The extract indicates that “clinical research CTGT products” are excluded (s 3). This matters because it signals that CTGT products used in clinical research may be governed by separate regulatory pathways (for example, clinical trial approvals and related requirements under the broader regulatory regime), rather than the licensing/registration scheme in these Regulations.
2) Manufacture: licensing and exceptions. Part 2 regulates CTGT product manufacture. Division 1 provides exceptions to the need for a manufacturer’s licence. For example, s 4 addresses manufacturing “minimally manipulated” CTGT products, and s 5 addresses manufacturing other CTGT products for research or non-clinical purposes. Division 2 then sets out the requirements for a manufacturer’s licence (s 6). Practically, this means that entities intending to manufacture CTGT products in Singapore must assess whether they fall within an exception or whether they must obtain a licence, and then comply with the licence conditions and operational requirements.
3) Import: licensing and exceptions. Part 3 mirrors the manufacture framework for importation. Division 1 provides exceptions, including importing minimally manipulated CTGT products (s 7) and importing to manufacture CTGT products (s 8). Division 2 sets requirements for an importer’s licence (s 9). For practitioners, the import provisions are often where compliance risk arises: importers must confirm whether the product is within an exception, whether the importer is importing for manufacturing purposes, and whether licensing is required before goods enter Singapore.
4) Supply: licensing, registration-related rules, and consent/information duties. Part 4 is central to day-to-day market access. It regulates wholesale supply and other supply pathways, including exceptions to licensing (Division 1) and licensing requirements for wholesalers (Division 3). Examples of exceptions include wholesale supply of minimally manipulated CTGT products (s 10), wholesale supply of other CTGT products for research or non-clinical purposes (s 11), and certain transfers by healthcare service licensees (s 12). There are also provisions for wholesale supply of CTGT products imported solely for export (s 13) and wholesale supply of self-manufactured CTGT products (s 14).
Division 2 addresses supply of CTGT products without registration. This is where the Regulations become particularly patient-facing. Section 15 provides “prescribed exceptions” to registration. Section 16 deals with supply of Class 1 CTGT products, while s 17 imposes a duty to obtain consent and provide information for supply of unregistered Class 2 CTGT products in certain circumstances. Section 18 covers supply of CTGT products manufactured under an agreement with a licensed or known manufacturer. The practical takeaway is that “unregistered” does not automatically mean “prohibited”; rather, the Regulations permit certain supplies but require heightened procedural safeguards (especially consent and information duties) for Class 2 products.
5) Supply requirements and record-keeping. Part 5 sets operational requirements. Section 20 regulates wholesale supply of Class 2 CTGT products. Sections 21 and 22 address supply by retail sale and supply by administration of CTGT products, respectively—reflecting that CTGT products may be supplied through different channels, including clinical administration. Section 23 requires records of supply of prescribed CTGT products. For counsel advising regulated entities, these provisions underscore that compliance is not only about obtaining licences/registration; it also involves maintaining auditable records of transactions and supply events.
6) Presentation: trade descriptions and required information. Part 6 focuses on how CTGT products are presented. Section 24 addresses trade descriptions. Section 25 requires information to be provided with CTGT products. Section 26 covers supply by dispensing. Section 27 addresses re-labelling of unregistered Class 2 CTGT products without a manufacturer’s licence, and s 28 provides corrective measures where there are contraventions of trade descriptions or failures to provide prescribed information. These provisions are significant for marketing, labelling, and pharmacy/dispensing workflows, and they create compliance obligations that can be triggered even where the underlying product is otherwise lawfully supplied.
7) Registration of CTGT products. Part 7 establishes the registration regime. Section 29 sets out requirements for registration of CTGT products. Section 29A (as shown in the extract) provides a prescribed time for cancellation of registration for non-payment of a retention fee—an important administrative compliance point. Section 30 requires disclosure of information on applications for registration. For practitioners, registration is the gateway to lawful supply in many cases; therefore, advising on the content of applications, supporting data, and ongoing fee obligations is essential.
8) Duties and obligations: quality, traceability, and safety reporting. Part 8 is a compliance engine. Division 1 sets general duties: routine inspections (s 31), maintaining records of manufacture (s 32), maintaining records of receipt and supply (s 33), maintaining a system of traceability (s 34), maintaining records of defects and adverse effects (s 35), reporting defects and adverse effects (s 36), and notifying the Authority concerning recall (s 37). Section 38 requires a supplier of an unregistered Class 1 CTGT product to provide information. Division 2 imposes duties specific to licensed and known manufacturers, importers and wholesalers, including duties to keep and provide information (ss 39–42), appointing a responsible person (s 43), and offences for contravention of duties (s 44). It also addresses changes affecting licences (s 45), changes affecting notices (s 46), and false notice (s 47). Division 3 imposes duties specific to registrants, including changes concerning registered CTGT products (s 48), information on validity of data (s 49), submission of benefit-risk evaluation reports (s 50), and duty to carry out a risk management plan (s 51). These provisions align Singapore’s CTGT oversight with modern pharmacovigilance and risk management expectations.
9) Certification for export and quality standards. Part 9 provides for certification of CTGT products intended for export (s 52) and certificates of manufacturing standard (s 53) and distribution standard (s 54), plus other certificates or documents (s 55). This is relevant for companies operating cross-border supply chains and for ensuring that export documentation reflects Singapore’s regulatory expectations.
10) General provisions: surveillance, non-compliance, confidentiality, and transitional rules. Part 10 includes product quality surveillances (s 56), handling of non-compliant CTGT products (s 57), confidentiality (s 58), and saving and transitional provisions (s 60). These provisions help manage enforcement and protect commercially sensitive information while ensuring continuity during regulatory transitions.
How Is This Legislation Structured?
The Regulations are organised into ten Parts plus a Schedule. Part 1 contains preliminary matters (citation, commencement, definitions, and exclusions for clinical research CTGT products). Parts 2 to 4 cover the lifecycle stages of CTGT products: manufacture (Part 2), import (Part 3), and supply (Part 4). Part 5 sets supply requirements, Part 6 governs presentation (trade descriptions and information/labelling). Part 7 introduces registration of CTGT products. Part 8 imposes duties and obligations on manufacturers, importers, wholesalers, and registrants, including traceability, record-keeping, adverse event reporting, recall notification, and risk management. Part 9 addresses certification for export. Part 10 contains general provisions including surveillance, confidentiality, and transitional arrangements.
Who Does This Legislation Apply To?
The Regulations apply to persons and entities involved in the manufacture, import, wholesale supply, retail supply, dispensing, and administration of CTGT products in Singapore. This includes licensed manufacturers and importers, licensed wholesalers, and registrants of CTGT products. It also extends to “known” manufacturers/importers/wholesalers referenced in the supply framework, and to suppliers who may be supplying unregistered products under specific exceptions.
Healthcare service licensees are also implicated, particularly where they transfer Class 2 CTGT products (s 12) and where administration occurs (s 22). Practitioners should therefore treat the Regulations as relevant not only to traditional pharmaceutical manufacturers and distributors, but also to clinical operators and supply-chain partners who handle CTGT products in practice.
Why Is This Legislation Important?
The CTGT Regulations are important because they operationalise Singapore’s regulatory control over high-risk, high-complexity therapies. CTGT products can present unique safety and quality challenges, including variability in biological materials, manufacturing consistency, and long-term risk profiles. By requiring licensing/registration, traceability systems, adverse event reporting, and risk management plans, the Regulations reduce the likelihood of unsafe products reaching patients.
From an enforcement and compliance perspective, the Regulations create multiple “touchpoints” where obligations arise: licensing decisions (Parts 2–4), ongoing supply and presentation compliance (Parts 5–6), and post-market responsibilities (Part 8). The inclusion of consent and information duties for unregistered Class 2 products (s 17) also highlights a patient-protection dimension beyond technical quality controls.
For lawyers advising regulated entities, the practical impact is significant: compliance requires mapping each activity (manufacture, import, supply, dispensing, administration) to the correct legal pathway (licence, registration, or exception), implementing record-keeping and traceability systems, ensuring labelling and trade description compliance, and maintaining pharmacovigilance and recall readiness. The timeline of amendments (including S 801/2023 and S 437/2023) further indicates that the regime is evolving; counsel should therefore verify the current version and track amendments affecting retention fees, registration cancellation timing, and operational duties.
Related Legislation
- Health Products Act (Cap. 122D): Authorising Act for the CTGT Regulations
- Healthcare Services Act 2020: Relevant to healthcare service licensees involved in transfers and administration
- Medical Registration Act 1997: Relevant to medical practitioners and professional regulatory context
- Dental Registration Act 1999: Relevant to dental practitioners where applicable to supply/administration contexts
Source Documents
This article provides an overview of the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.